Journal: Diabetes & Vascular Disease Research
Article Title: Mitochondrial mitophagy protection combining rivaroxaban and aspirin in high glucose-exposed human coronary artery endothelial cell. An in vitro study
doi: 10.1177/14791641221129877
Figure Lengend Snippet: Panel a.- Representative Western-blot of the Factor Xa (FXA) expression in human coronary artery endothelial cells (HCAEC) incubated with normal D-glucose concentration (5mmol/L, control) and in the presence of 30 mmol/L D-Glucose (+Glucose). Panel b.- Representative Western-blot of tissue factor (TF) expression in HCAEC incubated with normal D-glucose concentration (5 mmol/L, control) or with high glucose, 30 mmol/L D-Glucose (+Glucose). Experiments adding 50 nmol/L Rivaroxaban, 0.33 mmol/L ASA and 12.5 nmol/L Rivaroxaban +0.33 mmol/L ASA to high D-glucose-incubated HCAEC are also represented. Panel c.- Representative dot-blots to measure mitochondrial content of Pink-1 and Parkin proteins HCAEC incubated with 5 mmol/L D- (control) or 30 mmol/L D-Glucose (+Glucose). Experiments adding 50 nmol/L Rivaroxaban, 0.33 mmol/L ASA and 12.5 nmol/L Rivaroxaban +0.33 mmol/L ASA to high D-glucose-incubated HCAEC are also represented. Panel d.- Reactive oxygen species (ROS) production and changes in mitochondria membrane potential (ΔΨm) in HCAEC incubated with 5 mmol/L D- (control) or 30 mmol/L D-Glucose (+Glucose). Experiments adding 50 nmol/L Rivaroxaban, 0.33 mmol/L ASA and 12.5 nmol/L Rivaroxaban +0.33 mmol/L ASA to high D-glucose-incubated HCAEC are also represented. All experiments were also performed in presence of submaximal thrombin concentration (0.025 U/mL). Bar graphs of the four panels show the densitometric analysis represented in arbitrary units (A.U.). Results are represented as mean ± SEM of six different experiments. * p < 0.05 compared to the experiments performed normal glucose (5 mmol/L, control). # p < 0.05 compared to the experiments performed with 30 mmol/L glucose (+Glucose).
Article Snippet: The human coronary artery endothelial cell (HCAEC) line, (Ref. 350–05a, Merck KGaA, Germany) was incubated under the following experimental conditions: HCAEC incubated with physiologic D-glucose concentration (5 mmol/L, control group), HCAEC incubated with 30 mmol/L D-Glucose to mimic an hyperglycemic condition (+Glucose group), HCAEC incubated with 30 mmol/L D-Glucose+50 nmol/L Rivaroxaban (Bay 59–7939, Rivaroxaban group), HCAEC incubated with 30 mmol/L D-Glucose+0.33 mmol/L acetylsalicylic acid (ASA group) and 30 mmol/L D-glucose incubated HCAEC with Rivaroxaban (12.5 nmol/L) +ASA (0.33 mmol/L) (Riva+ASA group).
Techniques: Western Blot, Expressing, Incubation, Concentration Assay
